Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Jumps 61.4%

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 176,136 shares, a growth of 61.4% from the October 15th total of 109,110 shares. Based on an average daily trading volume, of 255,474 shares, the short-interest ratio is presently 0.7 days. Approximately 1.1% of the company’s shares are short sold.

Marker Therapeutics Stock Up 1.5%

Shares of Marker Therapeutics stock traded up $0.01 during trading hours on Wednesday, reaching $0.85. 44,433 shares of the company’s stock were exchanged, compared to its average volume of 151,027. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.46. The company has a market capitalization of $14.15 million, a P/E ratio of -2.18 and a beta of 1.65. The business has a fifty day moving average of $1.04 and a two-hundred day moving average of $1.31.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $1.29 million for the quarter, compared to analyst estimates of $2.12 million. As a group, research analysts predict that Marker Therapeutics will post -0.64 EPS for the current year.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned 0.41% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. Weiss Ratings lowered Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Finally, Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

View Our Latest Analysis on MRKR

Marker Therapeutics Company Profile

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

See Also

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.